ESR1 변이 전이성 유방암 : 시장 인사이트, 역학 및 시장 예측(2036년)

ESR1-mutated Metastatic Breast Cancer Insights and Trends

• The total cases of metastatic breast cancer in the US were approximately 164,000 in 2025. Furthermore, these cases are expected to increase by 2036.
• Estrogen receptor alpha (ERa), encoded by the ESR1 gene, is a member of the nuclear hormone receptor superfamily expressed in ~70% of newly diagnosed breast cancers.
• About 40% of advanced breast cancer patients develop ESR1 mutations during first-line therapy, reducing treatment effectiveness. HR+, HER2- breast cancer is commonly treated with aromatase and CDK4/6 inhibitors, but resistance often arises.
• The prevalence of ESR1 mutations is particularly high in patients previously exposed to aromatase inhibitors, making ESR1 mutation testing increasingly important in guiding treatment decisions.
• Liquid biopsy-based circulating tumor DNA (ctDNA) testing is emerging as a minimally invasive approach for detecting ESR1 mutations.
• There is a need for biomarkers to predict which patients with ESR1 mutations are likely to respond to different treatments. This would enable more personalized treatment approaches and could help improve patient outcomes.
• Elacestrant (ORSERDU) was is the first SERD approved specifically for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer following progression on endocrine therapy, marking a major endocrine therapy advancement in over two decades.
• The approval of vepdegestrant (VEPPANU) highlights growing industry confidence in targeted protein degradation technologies and positions vepdegestrant as a potential benchmark for next-generation endocrine therapies aimed at overcoming resistance following CDK4/6 inhibitor and prior endocrine treatment exposure.
• Vepdegestrant (VEPPANU) represents a significant shift in endocrine therapy for ESR1-mutated metastatic breast cancer as the first approved oral PROTAC estrogen receptor degrader, introducing a differentiated mechanism that actively eliminates the estrogen receptor rather than only inhibiting its signaling.
• The pipeline for ESR1-mutated Metastatic Breast Cancer is highly active and competitive. Key companies include Athira Pharma, AstraZeneca, Olema Pharmaceuticals, Roche (Genentech), and others.
• The emergence of next-generation selective estrogen receptor degraders (SERDs), proteolysis targeting chimeras (PROTACs), and combination regimens is expected to significantly expand the treatment landscape for ESR1-mutated metastatic breast cancer over the coming decade.

DelveInsight's 'ESR1-mutated Metastatic Breast Cancer - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the ESR1-mutated Metastatic Breast Cancer, historical and forecasted epidemiology, as well as the ESR1-mutated Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ESR1-mutated Metastatic Breast Cancer market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates ESR1-mutated Metastatic Breast Cancer patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in ESR1-mutated Metastatic Breast Cancer and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the ESR1-mutated Metastatic Breast Cancer Market

Rising Prevalence of ESR1 Mutations

ESR1 mutations commonly develop in patients with long-term exposure to endocrine therapies, especially aromatase inhibitors. These mutations lead to continuous activation of the estrogen receptor, even without estrogen present. As a result, they significantly contribute to disease progression in metastatic breast cancer.

Expansion of Next-Generation Endocrine Therapies

New classes such as oral SERDs, complete estrogen receptor antagonist (CERAN), and PROTAC degraders are transforming treatment options. These therapies aim to block or degrade the estrogen receptor more effectively than older drugs. They are designed specifically to address endocrine resistance in advanced disease.

Strong Clinical Pipeline and Drug Approvals

Recent approvals like elacestrant validate the clinical importance of targeting ESR1 mutations.

Multiple investigational agents are in Phase II and Phase III trials globally, including drugs such as camizestrant (AZD9833) and others.

ESR1-mutated Metastatic Breast Cancer Understanding and Treatment Algorithm

ESR1-mutated Metastatic Breast Cancer Overview and Diagnosis

ESR1-mutated metastatic breast cancer is a subtype of hormone receptor-positive (HR+), HER2-negative breast cancer in which mutations occur in the estrogen receptor gene (ESR1). These mutations typically develop during or after prolonged exposure to endocrine therapies, especially aromatase inhibitors. The mutation causes the estrogen receptor to become constitutively active, meaning it can signal cancer cell growth even in the absence of estrogen. As a result, the disease becomes more aggressive and resistant to standard hormone-based treatments, leading to progression in the metastatic setting.

The diagnosis of ESR1-mutated metastatic breast cancer is mainly performed using molecular testing techniques. The most common approach is a liquid biopsy, where circulating tumor DNA (ctDNA) is analyzed from a blood sample to detect ESR1 mutations non-invasively. Alternatively, tissue biopsy followed by next-generation sequencing (NGS) can also identify these mutations. Testing is usually recommended when there is disease progression during or after endocrine therapy, as identifying ESR1 mutations helps guide treatment decisions and switch to more effective targeted therapies.

Current ESR1-mutated Metastatic Breast Cancer Treatment Landscape

Treatment of ESR1-mutated metastatic breast cancer focuses on overcoming resistance to standard endocrine therapy. New-generation endocrine agents such as oral SERDs like elacestrant are commonly used, as they can inhibit mutant estrogen receptors more effectively. Emerging therapies, including SERDs, selective estrogen receptor modulators (SERMs), CERANs, and PROTAC-based degraders, are also under clinical investigation. In many cases, these agents are combined with targeted therapies such as CDK4/6 inhibitors to improve outcomes and delay disease progression. The overall goal of treatment is to control tumor growth, extend survival, and maintain quality of life.

ESR1-mutated Metastatic Breast Cancer Unmet Needs

The section "unmet needs of ESR1-mutated Metastatic Breast Cancer" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Surveillance and long-term monitoring

2. Lack of reimbursement programs

3. Early detection and diagnosis, and others.....

ESR1-mutated Metastatic Breast Cancer Epidemiology

Key Findings from ESR1-mutated Metastatic Breast Cancer Epidemiological Analysis and Forecast

• The total number of diagnosed prevalent cases of HR positive breast cancer in the 7MM was nearly 1.3 million in 2025.
• The total number of prevalent cases of breast cancer in the US was nearly 1.14 million in 2025.
• In 2025, among EU4 and the UK, Germany had the highest cases of ESR1-mutated HR positive metastatic breast cancer.
• According to SEER statistics, at the time of diagnosis, approximately 63% of breast cancer patients have local-stage breast cancer, 29% have the regional stage, and 6% have the distant (metastatic) disease while 2% remain in the unknown stage.

ESR1-mutated Metastatic Breast Cancer Drug Analysis & Competitive Landscape

The ESR1-mutated Metastatic Breast Cancer drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ESR1-mutated Metastatic Breast Cancer treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ESR1-mutated Metastatic Breast Cancer therapeutics market.

Approved Therapies for ESR1-mutated Metastatic Breast Cancer

Vepdegestrant (VEPPANU): Arvinas, Pfizer and Rigel Pharmaceuticals

Vepdegestrant, formerly known as ARV-471, is a first-in-class oral PROTAC estrogen receptor degrader jointly developed by Arvinas and Pfizer for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer, particularly in patients harboring ESR1 mutations. The drug gained significant attention following positive Phase III (VERITAC-2) trial results, which demonstrated improved progression-free survival (PFS) compared with fulvestrant in ESR1-mutated patients after progression on prior endocrine therapy and CDK4/6 inhibitors. With favorable efficacy profile, and potential use in earlier treatment settings and combination regimens, Vepdegestrant is emerging as a strong competitor within the rapidly evolving endocrine-resistant breast cancer market. Vepdegestrant was granted Fast Track designation (FTD) in February 2024 by the FDA, underscoring the significant unmet need in this patient population.

Elacestrant (ORSERDU): Stemline Therapeutics

Elacestrant is the first oral SERD approved to target ESR1-mutated tumors. Elacestrant received its first approval in 2023. As an oral medication, it offers a more convenient alternative to injectable therapies, and clinical studies such as the EMERALD trial have demonstrated its ability to improve disease control with manageable side effects.

Imlunestrant (INLURIYO): Eli Lilly and Company

Imlunestrant is an oral estrogen receptor antagonist that delivers continuous ER inhibition, including in estrogen receptor-1 (ESR1)-mutant cancers. The ER is the key therapeutic target for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It belongs to a class of drugs known as SERD, which work by both blocking and breaking down the estrogen receptor, a key driver of many breast cancers. Clinical trials have shown that imlunestrant can help control disease progression with manageable side effects like fatigue, nausea, and hot flashes, making it a promising advancement in breast cancer treatment.

ESR1-mutated Metastatic Breast Cancer Pipeline Analysis

Lasofoxifene: Sermonix Pharmaceuticals and Athira Pharma

Lasofoxifene, developed by Sermonix Pharmaceuticals, is an investigational oral SERM. The drug has shown promising efficacy and tolerability across the Phase II (ELAINE) studies, where lasofoxifene demonstrated numerically improved PFS compared with fulvestrant and encouraging outcomes in combination with abemaciclib. Sermonix is currently advancing the global Phase III (ELAINE-3) trial evaluating lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib in ESR1-mutated metastatic breast cancer. The drug has demonstrated promising Ki67 suppression and antitumor activity in neoadjuvant and aromatase inhibitor-resistant breast cancer models, potentially broadening its future market opportunity beyond ESR1-mutated populations.

Camizestrant (AZD9833): AstraZeneca

Camizestrant is an oral SERD that has shown antitumor efficacy in a range of preclinical models of breast cancer. The drug has been granted FTD and breakthrough designation (BTD) in the US for first-line HR+ HER2- ESR1 metastatic breast cancer. Currently, the drug is being evaluated in a Pivotal Phase III trial (SERENA-6) for first-line HR+ HER2- ESR1 metastatic breast cancer. According to AstraZeneca's H1 and Q2 2025 clinical trial results, a regulatory decision for camizestrant in ESR1-mutant HR+/HER2- metastatic breast cancer (1L switch, SERENA-6) is expected in H1 2026.

ESR1-mutated Metastatic Breast Cancer Key Players, Market Leaders and Emerging Companies

• Rigel Pharmaceuticals
• Athira Pharma
• Stemline Therapeutics
• Eli Lilly and Company
• Arvinas
• Pfizer
• AstraZeneca
• Olema Pharmaceuticals
• Genentech, and others

ESR1-mutated Metastatic Breast Cancer Drug Updates

• In May 2026, Arvinas and Pfizer announced that the US FDA has granted approval for vepdegestrant (VEPPANU) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer. This approval marks the first time the FDA has approved a PROTAC, a type of heterobifunctional protein degrader therapy.
• In May 2026, Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals, for the exclusive global development, manufacturing, and commercialization rights for vepdegestrant (VEPPANU).
• In December 2025, Athira Pharma announced that it has entered into an agreement to acquire the rights for the development and commercialization of lasofoxifene (excluding Asia and certain countries in the Middle East).
• In February 2025, AstraZeneca announced positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial, which showed that camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of PFS.
• In June 2025, AstraZeneca reported positive Phase III (SERENA-6) results, showing that the camizestrant + CDK4/6 inhibitor achieved a highly significant and clinically meaningful improvement in PFS.
• In August 2025, Arvinas and Pfizer announced that the US FDA had accepted the New Drug Application (NDA) for vepdegestrant for the treatment of patients with ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026.
• In September 2025, Arvinas provided an update on its collaboration with Pfizer for the co-development of vepdegestrant. Arvinas and Pfizer have jointly agreed to out-license the commercialization rights of vepdegestrant to a third party.
• In September 2025, the US FDA approved imlunestrant (INLURIYO), an ER antagonist, for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
• In December 2025, Eli Lilly and Company announced updated results from the Phase III (EMBER-3) study of INLURIYO in patients with ER+, HER2- metastatic breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.

ESR1-mutated Metastatic Breast Cancer Market Outlook

The treatment landscape of ESR1-mutated metastatic breast cancer has evolved from conventional endocrine-based therapy, such as aromatase inhibitors, toward targeted, mechanism-driven treatment approaches aimed at overcoming acquired resistance. However, the emergence of ESR1 mutations as a key resistance mechanism has shifted clinical practice toward more precise therapies that directly target the estrogen receptor pathway.

A major recent advancement in the ESR1-mutated metastatic breast cancer space is the approval of vepdegestrant (VEPPANU), a first-in-class oral PROTAC estrogen receptor degrader approved for ER+/HER2- advanced or metastatic breast cancer harboring ESR1 mutations. Elacestrant (ORSERDU) is the first oral SERD specifically approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer. It works by binding to and degrading the estrogen receptor, thereby inhibiting downstream signaling even in mutant forms of the receptor.

The pipeline for ESR1-mutated metastatic breast cancer continues to expand with several next-generation endocrine therapies. Lasofoxifene is a SERM, being developed for ESR1-mutated metastatic breast cancer and has shown encouraging efficacy in combination with CDK4/6 inhibitors in the (ELAINE) studies. The pipeline also includes oral SERDs such as camizestrant (AZD9833), and giredestrant (RO7247669), CERAN agents like palazestrant (OP-1250). These therapies aim to provide more complete estrogen receptor inhibition compared to earlier treatments and offer the convenience of oral administration.

Overall, the shift toward precision oncology-driven endocrine therapy is expected to drive steady growth in the 7MM ESR1-mutated Metastatic Breast Cancer market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest market size of ESR1-mutated Metastatic Breast Cancer. in 2025.
• Among approved therapies, vepdegestrant is expected to emerge as a key revenue driver in ESR1-mutated metastatic breast cancer, supported by its recent approval as a first-in-class oral PROTAC estrogen receptor degrader and its demonstrated efficacy in patients with prior endocrine therapy and CDK4/6 inhibitor resistance.
• The entry of late stage pipeline agents such as lasofoxifene, camizestrant (AZD9833), vepdegestrant (VEPPANU), and palazestrant (OP-1250) is anticipated to intensify competition and accelerate the shift toward next-generation endocrine therapies, including oral SERDs, CERANs, and PROTAC-based ER degraders, over the forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in ESR1-mutated Metastatic Breast Cancer (2022-2036 Forecast)

The ESR1-mutated metastatic breast cancer market comprises SERDs, CERANs, and PROTACs each targeting different aspects of ESR1-mutated Metastatic Breast Cancer.

• SERDs: Approved oral SERDs such as elacestrant (ORSERDU) and imlunestrant (INLURIYO) are gaining traction in the ESR1-mutated metastatic breast cancer market due to their ability to address endocrine resistance after CDK4/6 inhibitor progression. Pipeline candidate camizestrant (AZD9833) is emerging as a major competitor with promising efficacy and CNS activity, potentially strengthening AstraZeneca's position in the endocrine-resistant HR+/HER2- segment.
• CERANs: Pipeline candidate palazestrant (OP-1250) is a CERAN that completely blocks estrogen receptor signaling without partial agonist activity. Olema Pharmaceuticals is positioning the drug competitively through combination strategies with CDK4/6 inhibitors and by targeting endocrine-resistant populations where differentiation from established SERDs will be critical.
• PROTACs: Vepdegestrant (VEPPANU), has emerged as one of the most promising next-generation ER degraders and recently gained FDA approval for ESR1-mutated advanced/metastatic breast cancer. The trial results strengthened the competition within the endocrine-resistant breast cancer market. Its novel PROTAC mechanism and strong receptor degradation capability position it as a potential challenger to oral SERDs in future treatment sequencing strategies.

Targeted Immunotherapy defines the core innovation landscape driving market growth.

ESR1-mutated Metastatic Breast Cancer Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the ESR1-mutated metastatic breast cancer drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in ESR1-mutated metastatic breast cancer is expected to vary based on clinical positioning, mechanism of action, and stage of development. Approved therapies such as Vepdegestrant (VEPPANU), elacestrant (ORSERDU) and imlunestrant (INLURIYO) are expected to experience steady and clinically meaningful uptake in ESR1-mutated metastatic breast cancer supported by its targeted estrogen receptor degradation mechanism and demonstrated efficacy in patients with ESR1-mutated, ER+/HER2- advanced disease following progression on prior endocrine therapy.

In contrast, pipeline candidates such as lasofoxifene, camizestrant (AZD9833), vepdegestrant (VEPPANU), and palazestrant (OP-1250) are expected to demonstrate progressive uptake upon approval, as these therapies are designed to improve upon existing endocrine options by targeting key disease mechanisms.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in ESR1-mutated Metastatic Breast Cancer

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

ESR1-mutated Metastatic Breast Cancer Therapies Price Scenario & Trends

Pricing and analogue assessment of ESR1-mutated Metastatic Breast Cancer therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for ESR1-mutated Metastatic Breast Cancer

To keep up with ESR1-mutated Metastatic Breast Cancer market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the ESR1-mutated Metastatic Breast Cancer emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ESR1-mutated Metastatic Breast Cancer, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Harvard Medical School, Mass General Cancer Center, and Institut Curie and Universite Paris-Saclay, etc. were contacted.Their opinion helps understand and validate current and emerging ESR1-mutated Metastatic Breast Cancer therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ESR1-mutated Metastatic Breast Cancer.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of ESR1-mutated Metastatic Breast Cancer, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of ESR1-mutated Metastatic Breast Cancer, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ESR1-mutated Metastatic Breast Cancer market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ESR1-mutated Metastatic Breast Cancer market.

Report Insights

• ESR1-mutated Metastatic Breast Cancer Patient Population Forecast
• ESR1-mutated Metastatic Breast Cancer Therapeutics Market Size
• ESR1-mutated Metastatic Breast Cancer Pipeline Analysis
• ESR1-mutated Metastatic Breast Cancer Market Size and Trends
• ESR1-mutated Metastatic Breast Cancer Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• ESR1-mutated Metastatic Breast Cancer Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• ESR1-mutated Metastatic Breast Cancer Treatment Addressable Market (TAM)
• ESR1-mutated Metastatic Breast Cancer Competitive Landscape
• ESR1-mutated Metastatic Breast Cancer Major Companies Insights
• ESR1-mutated Metastatic Breast Cancer Price Trends and Analogue Assessment
• ESR1-mutated Metastatic Breast Cancer Therapies Drug Adoption/Uptake
• ESR1-mutated Metastatic Breast Cancer Therapies Peak Patient Share Analysis

Report Assessment

• ESR1-mutated Metastatic Breast Cancer Current Treatment Practices
• ESR1-mutated Metastatic Breast Cancer Unmet Needs
• ESR1-mutated Metastatic Breast Cancer Clinical Development Analysis
• ESR1-mutated Metastatic Breast Cancer Emerging Drugs Product Profiles
• ESR1-mutated Metastatic Breast Cancer Market attractiveness
• ESR1-mutated Metastatic Breast Cancer Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the ESR1-mutated Metastatic Breast Cancer market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of ESR1-mutated Metastatic Breast Cancer?
• What are the disease risks, burdens, and unmet needs of ESR1-mutated Metastatic Breast Cancer? What will be the growth opportunities across the 7MM concerning the patient population with ESR1-mutated Metastatic Breast Cancer?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of ESR1-mutated Metastatic Breast Cancer? What are the current guidelines for treating ESR1-mutated Metastatic Breast Cancer in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ESR1-mutated Metastatic Breast Cancer market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Catalyst
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of ESR1-mutated Metastatic Breast Cancer

6. ESR1-mutated Metastatic Breast Cancer Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of ESR1-mutated Metastatic Breast Cancer By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of ESR1-mutated Metastatic Breast Cancer By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of ESR1-mutated Metastatic Breast Cancer

• 7.1. Introduction
• 7.2. Causes
• 7.3. Signs And Symptoms
• 7.4. Diagnosis
  • 7.4.1. Differential Diagnosis
  • 7.4.2. Diagnostic Algorithm
  • 7.4.3. Diagnostic Guidelines

8. Epidemiology and Patient Population of ESR1-mutated Metastatic Breast Cancer

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the United States
  • 8.4.2. Stage-specific Diagnosed Prevalent Cases of HR Positive Breast Cancer in the United States
  • 8.4.3. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States
  • 8.4.4. Diagnosed Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in the United States
  • 8.4.5. Line-wise Treatable Cases of ESR1-mutated Metastatic Breast Cancer in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in EU4 and the UK
  • 8.5.2. Stage-specific Diagnosed Prevalent Cases of HR Positive Breast Cancer in EU4 and the UK
  • 8.5.3. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in EU4 and the UK
  • 8.5.4. Diagnosed Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in EU4 and the UK
  • 8.5.5. Line-wise Treatable Cases of ESR1-mutated Metastatic Breast Cancer in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in Japan
  • 8.6.2. Stage-specific Diagnosed Prevalent Cases of HR Positive Breast Cancer in Japan
  • 8.6.3. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan
  • 8.6.4. Diagnosed Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in Japan
  • 8.6.5. Line-wise Treatable Cases of ESR1-mutated Metastatic Breast Cancer in Japan

9. Patient Journey of ESR1-mutated Metastatic Breast Cancer

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of ESR1-mutated Metastatic Breast Cancer
• 10.2. Vepdegestrant (VEPPANU): Arvinas, Pfizer and Rigel Pharmaceuticals
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst Views
• 10.3. Elacestrant (ORSERDU): Stemline Therapeutics
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Summary of Pivotal Trials
  • 10.3.5. Analyst Views

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of ESR1-mutated Metastatic Breast Cancer
• 11.2. Lasofoxifene: Sermonix Pharmaceuticals and Athira Pharma
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trial Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst Views
• 11.3. Camizestrant (AZD9833): AstraZeneca
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Development
    • 11.3.3.1. Clinical Trial Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst Views

12. ESR1-mutated Metastatic Breast Cancer: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of ESR1-mutated Metastatic Breast Cancer
• 12.3. Conjoint Analysis of ESR1-mutated Metastatic Breast Cancer
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of ESR1-mutated Metastatic Breast Cancer in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of ESR1-mutated Metastatic Breast Cancer in the United States
  • 12.6.2. Market Size of ESR1-mutated Metastatic Breast Cancer by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of ESR1-mutated Metastatic Breast Cancer in EU4 and the UK
  • 12.7.2. Market Size of ESR1-mutated Metastatic Breast Cancer by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of ESR1-mutated Metastatic Breast Cancer in Japan
  • 12.8.2. Market Size of ESR1-mutated Metastatic Breast Cancer by Therapies in Japan

13. Unmet Needs of ESR1-mutated Metastatic Breast Cancer

14. SWOT Analysis of ESR1-mutated Metastatic Breast Cancer

15. KOL Views of ESR1-mutated Metastatic Breast Cancer

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of ESR1-mutated Metastatic Breast Cancer

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Market Access and Reimbursement of ESR1-mutated Metastatic Breast Cancer Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight